Abstract | OBJECTIVE: METHODS: Plasma was analysed in 26 GD1 patients treated with miglustat for up to 36 months. Ten patients were therapy-naïve and 16 had switched from enzyme replacement therapy (ERT); the interval between stopping ERT and starting SRT was 2-6 weeks. Plasma TC, triglycerides (TG), LDL-c, HDL-c, apolipoproteins ( apoA-I, apoB, and Lp[a]), C-reactive protein (CRP) concentrations, and chitotriosidase activity were measured before SRT (baseline) and at 12, 24, and 36 months follow up. RESULTS: In therapy-naïve patients, miglustat significantly increased plasma HDL-c and apoA-I, and slightly increased TC; while TG, CRP concentrations, and TC/HDL-c ratios decreased significantly after 24 months. In contrast, there were no changes in HDL-c and apoA-I, or in the TC/HDL-c ratio in switch patients. However, a decrease in CRP was observed after 12 months. LDL-c and apoB were not significantly altered in either patient group. CONCLUSIONS:
|
Authors | J Puzo, P Alfonso, P Irun, J Gervas, M Pocovi, P Giraldo |
Journal | Atherosclerosis
(Atherosclerosis)
Vol. 209
Issue 2
Pg. 515-9
(Apr 2010)
ISSN: 1879-1484 [Electronic] Ireland |
PMID | 19959168
(Publication Type: Controlled Clinical Trial, Journal Article, Research Support, Non-U.S. Gov't)
|
Copyright | Copyright 2009 Elsevier Ireland Ltd. All rights reserved. |
Chemical References |
- Apolipoprotein A-I
- Apolipoproteins B
- Cholesterol, HDL
- Cholesterol, LDL
- Lipoprotein(a)
- Triglycerides
- 1-Deoxynojirimycin
- C-Reactive Protein
- Cholesterol
- miglustat
|
Topics |
- 1-Deoxynojirimycin
(analogs & derivatives, therapeutic use)
- Adult
- Aged
- Apolipoprotein A-I
(blood)
- Apolipoproteins B
(blood)
- C-Reactive Protein
(metabolism)
- Cholesterol
(blood)
- Cholesterol, HDL
(blood)
- Cholesterol, LDL
(blood)
- Coronary Disease
(etiology)
- Female
- Gaucher Disease
(drug therapy)
- Humans
- Lipoprotein(a)
(metabolism)
- Male
- Middle Aged
- Risk
- Triglycerides
(blood)
|